ACTU (Actuate Therapeutics) Insider Ownership : 0.65 % (As of Apr. 28, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Actuate Therapeutics's insider ownership is 0.65%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Actuate Therapeutics's Institutional Ownership is 51.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Actuate Therapeutics's Float Percentage Of Total Shares Outstanding is 30.84%.

Actuate Therapeutics Insider Ownership Historical Data

The historical data trend for Actuate Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Insider Ownership Chart

Actuate Therapeutics Historical Data

The historical data trend for Actuate Therapeutics can be seen below:

	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Insider Ownership	0.66	0.65	0.65	0.65	0.65	0.65	0.65	0.65

Actuate Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.